- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 15, Issue 3, 2014
Current Drug Targets - Volume 15, Issue 3, 2014
Volume 15, Issue 3, 2014
-
-
Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Chagas disease is endemic in Latin America and is caused by the protozoan hemoflagellate parasite Trypanosoma cruzi. Nowadays, it has also been disseminated to non-endemic countries due to the ease of global mobility. The nitroheterocycle benznidazole is currently used to treat this neglected tropical disease, although this drug causes severe side effects and has limited efficacy during the chronic phase of the diseas Read More
-
-
-
Pannexin Channels: The Emerging Therapeutic Targets
Authors: Misbahuddin Mohammad and Hamed Said HabibIntercellular communication plays a pivotal role in various physiological functions. This is mainly done through gap junctions and trans-membrane channels. The structural proteins forming these channels are different in vertebrates and invertebrates namely connexins and innexins respectively. Recently, a new class of proteins playing a crucial role in intercellular communication was discovered and named pannexins. They are fo Read More
-
-
-
Microneedle-Based Drug Delivery Systems for Transdermal Route
Authors: Maria Bernadete Riemma Pierre and Fabia Cristina RossettiTransdermal delivery offers an attractive, noninvasive administration route but it is limited by the skin’s barrier to penetration. Minimally invasive techniques, such as the use of microneedles (MNs), bypass the stratum corneum (SC) barrier to permit the drug’s direct access to the viable epidermis. These novel micro devices have been developed to puncture the skin for the transdermal delivery of hydrophilic drugs and m Read More
-
-
-
Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Authors: Kunal Jain, Sumeet Sood and Kuppusamy GowthamarajanMalaria is the most serious tropical disease of humankind and a cause of much debilitation and morbidity throughout the world especially in endemic areas like India and Africa. The development of drug resistance may be due to insufficient drug concentration in presence of high parasite load. In addition, the present pharmaceutical dosage forms are ineffective thereby necessitating the development of novel dosage form Read More
-
-
-
Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Authors: Ana C. Brett, Tatiana R. Rosenstock and A. Cristina RegoHuntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve Read More
-
-
-
Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Authors: Jintong Du, Yu Qiao, Lele Sun and Xiuwen WangLymphoid-tyrosine phosphatase (Lyp), encoded by the PTPN22 gene, is a member of the protein tyrosine phosphatase family enzymes. Human genetics studies have shown that a single-nucleotide polymorphism in PTPN22 is often mutated in patients suffering from autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosis. Because of its critical role in the regulation of T-cell Rec Read More
-
-
-
COX-2 Signaling and Cancer: New Players in Old Arena
Authors: Shashank Misra and Kulbhushan SharmaCancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
